185 related articles for article (PubMed ID: 109512)
21. The terminal stages of immune hemolysis--a brief review.
Boyle MD; Borsos T
Mol Immunol; 1980 Mar; 17(3):425-32. PubMed ID: 6255318
[No Abstract] [Full Text] [Related]
22. Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels.
Zalman LS; Wood LM; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1986 Sep; 83(18):6975-9. PubMed ID: 2428045
[TBL] [Abstract][Full Text] [Related]
23. Complement induces a transient increase in membrane permeability in unlysed erythrocytes.
Halperin JA; Nicholson-Weller A; Brugnara C; Tosteson DC
J Clin Invest; 1988 Aug; 82(2):594-600. PubMed ID: 3403718
[TBL] [Abstract][Full Text] [Related]
24. On the mechanism of cell membrane damage by complement: evidence on insertion of polypeptide chains from C8 and C9 into the lipid bilayer of erythrocytes.
Hammer CH; Shin ML; Abramovitz AS; Mayer MM
J Immunol; 1977 Jul; 119(1):1-8. PubMed ID: 559700
[TBL] [Abstract][Full Text] [Related]
25. Complement lysis: the ultrastructure and orientation of the C5b-9 complex on target sheep erythrocyte membranes.
Tranum-Jensen J; Bhakdi S; Bhakdi-Lehnen B; Bjerrum OJ; Speth V
Scand J Immunol; 1978; 7(1):45-6. PubMed ID: 635472
[TBL] [Abstract][Full Text] [Related]
26. Quantitative measurement of C9 sites and their association to the ring-like "lesions" on complementlysed membranes: a morphometric immunoferritin study.
Rauterberg EW; Ungemach B; Gebest HJ
J Immunol; 1979 Jan; 122(1):355-65. PubMed ID: 570204
[No Abstract] [Full Text] [Related]
27. The attack phase of human complement: differentiation between membrane binding and complex formation by the detection of neoantigen expression in situ. A morphometric immunoferritin study.
Balkarowa-Ständer J; Rother U; Rauterberg EW
J Immunol; 1981 Sep; 127(3):1089-93. PubMed ID: 7264298
[TBL] [Abstract][Full Text] [Related]
28. The relationship between channel size and the number of C9 molecules in the C5b-9 complex.
Ramm LE; Whitlow MB; Mayer MM
J Immunol; 1985 Apr; 134(4):2594-9. PubMed ID: 2579147
[TBL] [Abstract][Full Text] [Related]
29. Lytic activity of C5-9 complexes for erythrocytes from the species other than sheep: C9 rather than C8-dependent variation in lytic activity.
Yamamoto KI
J Immunol; 1977 Oct; 119(4):1482-5. PubMed ID: 894048
[TBL] [Abstract][Full Text] [Related]
30. C3-independent immune haemolysis: mechanism of membrane attack complex formation.
Kitamura H; Tsuboi M; Nagaki K
Immunology; 1986 Sep; 59(1):147-51. PubMed ID: 3759127
[TBL] [Abstract][Full Text] [Related]
31. Electron spin resonance studies on interaction of complement proteins with erythrocyte membranes.
Dahl CE; Levine RP
Proc Natl Acad Sci U S A; 1978 Oct; 75(10):4930-4. PubMed ID: 217005
[TBL] [Abstract][Full Text] [Related]
32. Mapping of the complement C9 binding domain in paramyosin of the blood fluke Schistosoma mansoni.
Deng J; Gold D; LoVerde PT; Fishelson Z
Int J Parasitol; 2007 Jan; 37(1):67-75. PubMed ID: 17123534
[TBL] [Abstract][Full Text] [Related]
33. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9.
Shin ML; Hänsch G; Hu VW; Nicholson-Weller A
J Immunol; 1986 Mar; 136(5):1777-82. PubMed ID: 2419414
[TBL] [Abstract][Full Text] [Related]
34. Reaction of partial identity between the C56-9 complex derived from target membranes and from inulin-activated serum.
Bhakdi S; Bhakdi-Lehnen B; Ey P; Bjerrum OJ
Monogr Allergy; 1977; 12():56-61. PubMed ID: 411027
[No Abstract] [Full Text] [Related]
35. Species-restricted target cell lysis by human complement: complement-lysed erythrocytes from heterologous and homologous species differ in their ratio of bound to inserted C9.
Hu VW; Shin ML
J Immunol; 1984 Oct; 133(4):2133-7. PubMed ID: 6470486
[TBL] [Abstract][Full Text] [Related]
36. Regulation of complement functional efficiency by histidine-rich glycoprotein.
Chang NS; Leu RW; Rummage JA; Anderson JK; Mole JE
Blood; 1992 Jun; 79(11):2973-80. PubMed ID: 1375119
[TBL] [Abstract][Full Text] [Related]
37. Restriction of cell lysis by homologous complement: I. An analysis of membrane attack complex formation on target membranes.
Houle JJ; Hoffmann EM; Esser AF
Blood; 1988 Feb; 71(2):280-6. PubMed ID: 3337896
[TBL] [Abstract][Full Text] [Related]
38. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.
Meri S; Morgan BP; Davies A; Daniels RH; Olavesen MG; Waldmann H; Lachmann PJ
Immunology; 1990 Sep; 71(1):1-9. PubMed ID: 1698710
[TBL] [Abstract][Full Text] [Related]
39. Activation of the fifth and sixth component of the complement system: similarities between C5b6 and C(56)a with respect to lytic enhancement by cell-bound C3b or A2C, and species preferences of target cell.
Hänsch GM; Hammer CH; Mayer MM; Shin ML
J Immunol; 1981 Sep; 127(3):999-1002. PubMed ID: 6911149
[TBL] [Abstract][Full Text] [Related]
40. Complement lysis: evidence for an amphiphilic nature of the terminal membrane C5b-9 complex of human complement.
Bhakdi S; Bjerrum OJ; Bhakdi-Lehnen B; Tranum-Jensen J
J Immunol; 1978 Dec; 121(6):2526-32. PubMed ID: 569173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
